Stay updated on Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.

Latest updates to the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page
- Check7 days agoChange DetectedThe footer revision label changes from v3.7.0 to v3.7.1, while the page continues to display a 403 error.SummaryDifference0.2%

- Check14 days agoNo Change Detected
- Check21 days agoChange DetectedThe page now displays a 403 Forbidden error with a simple header and a Home link, indicating restricted access rather than active content. The previously visible study details have been removed, leaving an error state.SummaryDifference19%

- Check28 days agoChange DetectedRevision: v3.7.0 was added and Revision: v3.6.6 was removed, indicating a new page version in the site's revision history. This update does not alter page content or user-facing features.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page's revision tag was updated from v3.6.5 to v3.6.6, indicating a background update to the site or content-management system.SummaryDifference0.0%

- Check49 days agoChange DetectedAn NIH grant/contract line for 2019 was added, and a new publication citation (Regnault et al., 2024) regarding tolerability in LIBRETTO-531 was also added.SummaryDifference0.0%

- Check63 days agoChange DetectedA new Revision: v3.6.5 was added and the previous Revision: v3.6.4 was removed, indicating a minor update to the page's version metadata.SummaryDifference0.0%

Stay in the know with updates to Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET-Mutant Medullary Thyroid Cancer Clinical Trial page.